| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total other expenses, net | -330 | -471 | -717 | -1,471 |
| Net income before income taxes | 9,243 | 6,165 | 3,267 | 20,608 |
| Us-gaap_incometaxexpensebenefit | - | - | - | 291 |
| Income tax expense | 399 | 310 | 293 | - |
| Net income | 8,844 | 5,855 | 2,974 | 20,317 |
| Basic (in dollars per share) | 0.18 | 0.12 | 0.06 | 0.41 |
| Diluted (in dollars per share) | 0.17 | 0.12 | 0.06 | 0.41 |
| Weighted average common stock outstanding for basic net income per share (in shares) | 50,339,456 | 49,700,217 | 49,595,697 | 49,008,464 |
| Weighted-average shares of common stock outstandingdiluted (in shares) | 50,929,893 | 50,144,704 | 49,906,341 | 49,173,361 |
PUMA BIOTECHNOLOGY, INC. (PBYI)
PUMA BIOTECHNOLOGY, INC. (PBYI)